SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 1 USD
0.00%
Market Price
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
43.91
45.05
Годовой диапазон
42.45
59.68
Дневное изменение
+0.39%
Месячное изменение
-12.96%
6-месячное изменение
-19.09%
Годовое изменение
-18.69%
Предыдущее закрытие
43.7 4
Open
45.0 5
Low
43.9 1
High
45.0 5
Volume
85
Открыть полный график

Financials

Обзор Отчетность Статистика Документы

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 19 May 2015

Full document

Business Context and Reporting Period

This Form 8-K filing by Supernus Pharmaceuticals, Inc. covers events occurring on May 19, 2015, and the Annual Meeting of Stockholders held on May 21, 2015. The report details the results of shareholder votes and announces upcoming investor relations activities.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.

Material Changes and Corporate Actions

Annual Meeting Results

As of March 23, 2015, there were 46,779,242 shares of common stock outstanding and entitled to vote. The voting results were as follows:

  • Proposal 1 (Election of Class III Directors):
    • Georges Gemayel, Ph.D.: 34,214,266 votes For; 197,564 votes Withheld; 7,557,607 Broker Non-Votes.
    • John M. Siebert, Ph.D.: 34,206,073 votes For; 205,757 votes Withheld; 7,557,607 Broker Non-Votes.
  • Proposal 2 (Ratification of Auditors): Ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2015.
    • Votes For: 41,876,451
    • Votes Against: 75,064
    • Abstain: 17,922

Other Events

On May 19, 2015, the Company announced that management will present an overview and update and host investor meetings at the Jefferies Healthcare Conference on June 2, 2015.

Guidance, Outlook, and Risks

The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclosure of the upcoming conference presentation.

Key Facts for Investor Verification

  • Verify the successful election of Class III Directors Georges Gemayel and John M. Siebert.
  • Confirm the ratification of Ernst & Young LLP as the independent auditor for the 2015 fiscal year.
  • Note the scheduled investor presentation at the Jefferies Healthcare Conference on June 2, 2015.
  • Review the definitive proxy statement filed on March 30, 2015, for additional context on the proposals.

Новости